Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CR4056 in knee osteoarthritis pain
2015-001136-37Phase 2Completed
- Sponsor
- Rottapharm Biotech
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in knee osteoarthritis (OA) comparing CR4056 with Placebo (2 arms). Primary endpoint: Mean change from baseline in WOMAC Pain Subscale at end of double-blind treatment. Started May 2015; status: completed.
02
Drugs
CR4056
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2015-001136-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001136-37.